KRAS and non-small cell lung carcinoma: The anti-cancer properties in NSCLC treatments, their role in metabolic reprogramming, and the synergistic effects with KDAC inhibitors of these chemical agents support the purpose of considering the drugs proposed by our machine learning approach for targeting metabolic reprogramming of KRAS-mutated NSCLC treatment upon hypoxia conditions.